The evolution of treatment options over the past 20 years has provided for a normal life expectancy for most patients with chronic myeloid leukemia. Currently approved tyrosine kinase inhibitors mainly differ in potency and side effect profile. Flumatinib goes for deep responses and good tolerability.

See related article by Zhang et al., p. 70

©2020 American Association for Cancer Research.
2020
American Association for Cancer Research.
You do not currently have access to this content.